PQB Stock Overview
A biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pure Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł1.52 |
| 52 Week High | zł4.61 |
| 52 Week Low | zł1.17 |
| Beta | 1.28 |
| 1 Month Change | 0% |
| 3 Month Change | 22.19% |
| 1 Year Change | -56.26% |
| 3 Year Change | -93.97% |
| 5 Year Change | -71.60% |
| Change since IPO | -63.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| PQB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | 3.0% |
| 1Y | -56.3% | -3.8% | 12.8% |
Return vs Industry: PQB underperformed the German Biotechs industry which returned 34.1% over the past year.
Return vs Market: PQB underperformed the German Market which returned 7.5% over the past year.
Price Volatility
| PQB volatility | |
|---|---|
| PQB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PQB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PQB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 56 | n/a | purebiologics.com |
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.
Pure Biologics S.A. Fundamentals Summary
| PQB fundamental statistics | |
|---|---|
| Market cap | €6.11m |
| Earnings (TTM) | -€7.33m |
| Revenue (TTM) | €25.21k |
242.4x
P/S Ratio-0.8x
P/E RatioIs PQB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PQB income statement (TTM) | |
|---|---|
| Revenue | zł109.00k |
| Cost of Revenue | zł4.43m |
| Gross Profit | -zł4.32m |
| Other Expenses | zł27.40m |
| Earnings | -zł31.72m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -9.53 |
| Gross Margin | -3,960.55% |
| Net Profit Margin | -29,097.25% |
| Debt/Equity Ratio | 94.7% |
How did PQB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/24 12:35 |
| End of Day Share Price | 2023/12/27 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pure Biologics S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sylwia Jaskiewicz | Dom Maklerski Banku Ochrony Srodowiska S.A. |